Clinical medication response under new major infectious disease: off-label use and compassionate use / 药学实践杂志
Journal of Pharmaceutical Practice
;
(6): 207-210, 2020.
Article
in Chinese
| WPRIM
| ID: wpr-821471
ABSTRACT
At present, there are no specific targeted drugs for the treatment of pneumonia (COVID-19) caused by the novel coronavirus (SARS-CoV-2). Interferon, lopinavir/ritonavir, ribavirin, chloroquine phosphate were chosen as off-label use, and remdesivir was chosen as compassionate use. This paper reviewed the behavior of the two medication response to the new major infectious disease.
Full text:
Available
Index:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
Journal of Pharmaceutical Practice
Year:
2020
Type:
Article
Similar
MEDLINE
...
LILACS
LIS